Tome Biosciences is a genomic medicine company. By creating programmable gene insertion technology, Tome Biosciences has a mission to deliver patients a cure with cell technology. The company’s integrative gene therapies work by destroying deoxyribonucleic acid and inserting a genetic sequence at any location of any size. Tome Biosciences was founded by Jonathan Gootenberg and Omar Abudayyeh in 2021 and is headquartered in Boston, MA.
Tome Biosciences is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Tome Biosciences pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Tome Biosciences is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.